Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:KRYS NASDAQ:NUVL NASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$74.31-3.6%$64.00$29.31▼$80.20$9.20B0.382.04 million shs954,311 shsKRYSKrystal Biotech$285.88+0.5%$262.18$122.80▼$303.00$8.42B0.5290,734 shs64,856 shsNUVLNuvalent$102.96+1.5%$101.96$63.56▼$113.01$8.10B1.15560,631 shs39,667 shsTYRATyra Biosciences$34.13+0.6%$35.96$8.75▼$40.65$2.04B0.79975,744 shs43,494 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+21.69%+27.02%+15.53%+21.36%+110.23%KRYSKrystal Biotech+6.97%+5.68%+9.05%+5.74%+75.35%NUVLNuvalent+2.45%-0.46%-3.76%-3.35%+34.52%TYRATyra Biosciences-0.32%-3.22%-14.34%+10.27%+223.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$74.31-3.6%$64.00$29.31▼$80.20$9.20B0.382.04 million shs954,311 shsKRYSKrystal Biotech$285.88+0.5%$262.18$122.80▼$303.00$8.42B0.5290,734 shs64,856 shsNUVLNuvalent$102.96+1.5%$101.96$63.56▼$113.01$8.10B1.15560,631 shs39,667 shsTYRATyra Biosciences$34.13+0.6%$35.96$8.75▼$40.65$2.04B0.79975,744 shs43,494 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+21.69%+27.02%+15.53%+21.36%+110.23%KRYSKrystal Biotech+6.97%+5.68%+9.05%+5.74%+75.35%NUVLNuvalent+2.45%-0.46%-3.76%-3.35%+34.52%TYRATyra Biosciences-0.32%-3.22%-14.34%+10.27%+223.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.82Moderate Buy$92.7024.76% UpsideKRYSKrystal Biotech 2.83Moderate Buy$324.1113.37% UpsideNUVLNuvalent 2.88Moderate Buy$137.2533.31% UpsideTYRATyra Biosciences 2.92Moderate Buy$46.5036.26% UpsideCurrent Analyst Ratings BreakdownLatest TYRA, NUVL, KRYS, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026CYTKCytokinetics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/6/2026CYTKCytokinetics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$119.005/6/2026CYTKCytokinetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/6/2026CYTKCytokinetics Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$108.005/5/2026CYTKCytokinetics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$106.005/5/2026KRYSKrystal Biotech EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$300.005/5/2026KRYSKrystal Biotech CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$371.00 ➝ $378.005/5/2026CYTKCytokinetics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$85.00 ➝ $102.005/4/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$310.004/21/2026NUVLNuvalent Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026NUVLNuvalent HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$155.00(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$88.04M104.86N/AN/A($5.39) per share-13.79KRYSKrystal Biotech$389.13M21.63$7.26 per share39.36$43.37 per share6.59NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/ATYRATyra BiosciencesN/AN/AN/AN/A$4.86 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$784.96M-$6.53N/AN/AN/A-891.60%N/A-49.62%N/AKRYSKrystal Biotech$204.83M$6.8538.2526.01N/A53.92%19.25%17.62%N/ANUVLNuvalent-$425.38M-$5.85N/AN/AN/AN/A-39.29%-35.01%5/7/2026 (Estimated)TYRATyra Biosciences-$119.95M-$2.01N/AN/AN/AN/A-41.17%-38.40%5/14/2026 (Estimated)Latest TYRA, NUVL, KRYS, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026TYRATyra Biosciences-$0.60N/AN/AN/AN/AN/A5/7/2026Q1 2026NUVLNuvalent-$1.35N/AN/AN/A$0.49 millionN/A5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 million3/2/2026Q4 2025TYRATyra Biosciences-$0.54-$0.57-$0.03-$0.57N/AN/A2/24/2026Q4 2025CYTKCytokinetics-$1.48-$1.50-$0.02-$1.50$8.02 million$17.76 million2/17/2026Q4 2025KRYSKrystal Biotech$1.62$1.70+$0.08$1.70$105.30 million$107.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A4.534.53KRYSKrystal BiotechN/A9.959.56NUVLNuvalentN/A15.2715.27TYRATyra BiosciencesN/A14.6714.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AKRYSKrystal Biotech86.29%NUVLNuvalent97.26%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.60%KRYSKrystal Biotech13.10%NUVLNuvalent10.20%TYRATyra Biosciences12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250124.24 million121.01 millionOptionableKRYSKrystal Biotech21029.44 million25.58 millionOptionableNUVLNuvalent4078.62 million70.60 millionOptionableTYRATyra Biosciences2059.49 million52.05 millionOptionableTYRA, NUVL, KRYS, and CYTK HeadlinesRecent News About These CompaniesTyra Biosciences faces earnings test ahead of key trial dataApril 29, 2026 | investing.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Recommendation of "Moderate Buy" by AnalystsApril 27, 2026 | marketbeat.comTyra Bioscience, IncApril 25, 2026 | edition.cnn.comTyra Bioscience (TYRA) Receives a Buy from OppenheimerApril 25, 2026 | theglobeandmail.comGuggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug DabogratinibApril 24, 2026 | insidermonkey.comTyra Biosciences, Inc. ($TYRA) CEO 2025 Pay RevealedApril 17, 2026 | quiverquant.comQTyra Biosciences Announces Appointment of Habib Dable to its Board of DirectorsApril 17, 2026 | prnewswire.comGuggenheim initiates coverage of Tyra Biosciences (TYRA) with buy recommendationApril 16, 2026 | msn.comTyra Biosciences (NASDAQ:TYRA) Stock Rating Upgraded by GuggenheimApril 16, 2026 | marketbeat.comJPMorgan Chase & Co. Trims Position in Tyra Biosciences, Inc. $TYRAApril 11, 2026 | marketbeat.comCanaccord Genuity initiates coverage of Tyra Biosciences (TYRA) with buy recommendationApril 7, 2026 | msn.comCanaccord Genuity Group Begins Coverage on Tyra Biosciences (NASDAQ:TYRA)April 6, 2026 | marketbeat.comA Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial ProgressApril 4, 2026 | finance.yahoo.comTyra Bioscience Strengthens Financial Leadership with New OfficerApril 2, 2026 | tipranks.comGilla Kaplan Sells 14,295 Shares of Tyra Biosciences (NASDAQ:TYRA) StockMarch 29, 2026 | insidertrades.comThis Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New PositionMarch 20, 2026 | fool.comTyra Bioscience Raises $126 Million in Block Share SaleMarch 4, 2026 | tipranks.comDid Deeper Losses and Dabogratinib Progress Just Shift Tyra Biosciences' (TYRA) Investment Narrative?March 4, 2026 | finance.yahoo.comTyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent HighlightsMarch 2, 2026 | prnewswire.comCantor Fitzgerald initiates coverage of Tyra Biosciences (TYRA) with overweight recommendationFebruary 24, 2026 | msn.comTyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers SymposiumFebruary 23, 2026 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTYRA, NUVL, KRYS, and CYTK Company DescriptionsCytokinetics NASDAQ:CYTK$74.31 -2.79 (-3.61%) As of 11:08 AM Eastern This is a fair market value price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$285.88 +1.31 (+0.46%) As of 11:08 AM Eastern This is a fair market value price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvalent NASDAQ:NUVL$102.96 +1.49 (+1.47%) As of 11:08 AM Eastern This is a fair market value price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Tyra Biosciences NASDAQ:TYRA$34.12 +0.20 (+0.57%) As of 11:08 AM Eastern This is a fair market value price provided by Massive. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Just How Big a Problem Could Amazon’s Cash Burn Rate Be? BlackBerry Rewrites Its Own Operating System Grab Holdings Faces Hurdles, But Upside Potential Is Hard to Ignore Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
